Moderna Announces FDA Delay in RSV Vaccine Review

Friday, 10 May 2024, 11:45

Moderna, based in Cambridge, Mass., revealed that the FDA will not finalize the review of its RSV vaccine by the initial May 12 deadline, attributing the delay to administrative constraints. This regulatory setback may impact the expected timeline for the vaccine's potential approval.

https://store.livarava.com/2b7c4b7d-0ec3-11ef-a6c2-63e1980711b2.jpg — Moderna Announces FDA Delay in RSV Vaccine Review

Moderna FDA Review Delay

Moderna, a biotech company headquartered in Cambridge, Mass., disclosed that the FDA will not complete the review of its RSV vaccine by the original May 12 deadline due to administrative constraints.

Regulatory Setback

This delay may affect the anticipated timeline for the potential approval of Moderna's RSV vaccine, highlighting uncertainties in the regulatory process.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.